CA2411971A1 - Proteases - Google Patents

Proteases Download PDF

Info

Publication number
CA2411971A1
CA2411971A1 CA002411971A CA2411971A CA2411971A1 CA 2411971 A1 CA2411971 A1 CA 2411971A1 CA 002411971 A CA002411971 A CA 002411971A CA 2411971 A CA2411971 A CA 2411971A CA 2411971 A1 CA2411971 A1 CA 2411971A1
Authority
CA
Canada
Prior art keywords
polynucleotide
polypeptide
seq
amino acid
prts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002411971A
Other languages
English (en)
French (fr)
Inventor
Henry Yue
Vicki S. Elliott
Ameena R. Gandhi
Preeti Lal
Janice Au-Young
Catherine M. Tribouley
Angelo M. Delegeane
Mariah R. Baughn
Danniel B. Nguyen
Ernestine A. Lee
April Hafalia
Farrah A. Khan
Narinder K. Chawla
Monique G. Yao
Dyung Aina M. Lu
Chandra S. Arvizu
Y. Tom Tang
Roderick T. Walsh
Yalda Azimzai
Yan Lu
Jayalaxmi Ramkumar
Yuming Xu
Roopa Reddy
Debopriya Das
Liam Kearney
Deborah A. Kallick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2411971A1 publication Critical patent/CA2411971A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002411971A 2000-06-16 2001-06-13 Proteases Abandoned CA2411971A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US21233600P 2000-06-16 2000-06-16
US60/212,336 2000-06-16
US21395500P 2000-06-22 2000-06-22
US60/213,955 2000-06-22
US21539600P 2000-06-29 2000-06-29
US60/215,396 2000-06-29
US21682100P 2000-07-07 2000-07-07
US60/216,821 2000-07-07
US21894600P 2000-07-14 2000-07-14
US60/218,946 2000-07-14
PCT/US2001/019178 WO2001098468A2 (en) 2000-06-16 2001-06-13 Proteases

Publications (1)

Publication Number Publication Date
CA2411971A1 true CA2411971A1 (en) 2001-12-27

Family

ID=27539651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002411971A Abandoned CA2411971A1 (en) 2000-06-16 2001-06-13 Proteases

Country Status (5)

Country Link
EP (1) EP1292684A2 (ja)
JP (1) JP2004515217A (ja)
AU (1) AU2001269836A1 (ja)
CA (1) CA2411971A1 (ja)
WO (1) WO2001098468A2 (ja)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096391A1 (en) * 2000-12-22 2003-05-22 Millennium Pharmaceuticals, Inc. 17903, a novel human aminopeptidase and uses therefor
JP3356771B2 (ja) * 1999-11-11 2002-12-16 山之内製薬株式会社 アグリカナーゼ活性を有する新規な金属プロテアーゼ
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP1280922A2 (en) * 2000-04-18 2003-02-05 Millennium Pharmaceuticals, Inc. 21953, a human prolyl oligopeptidase family member and uses thereof
US20030083244A1 (en) * 2000-04-26 2003-05-01 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
CA2408105A1 (en) * 2000-05-04 2001-11-08 Sugen, Inc. Novel proteases
AU2001287555A1 (en) * 2000-06-23 2002-01-02 Bayer Aktiengesellschaft Regulation of human prostasin-like serine protease
WO2002000853A2 (en) 2000-06-26 2002-01-03 Bayer Aktiengesellschaft Regulation of human caspase-1-like protease
AU2002222937A1 (en) * 2000-07-18 2002-01-30 Millennium Pharmaceuticals, Inc. 14087, a serine protease molecule and uses therefor
AU2001293718A1 (en) * 2000-08-07 2002-02-18 Bayer Aktiengesellschaft Regulation of human membrane-type serine protease
GB0020345D0 (en) * 2000-08-17 2000-10-04 Glaxo Group Ltd Protein
AU2001288339B2 (en) * 2000-08-22 2005-09-29 Lexicon Pharmaceuticals, Inc. Novel human proteases and polynucleotides encoding the same
WO2002026949A2 (en) * 2000-09-29 2002-04-04 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
CZ20031301A3 (cs) * 2000-10-12 2003-10-15 Ferring Bv Izolovaná nukleová kyselina, polypeptid, expresní vektor a protilátka
US20020119555A1 (en) * 2000-12-22 2002-08-29 Rajasehkar Bandaru 53014, a human metalloprotease family member and uses therefor
GB0101760D0 (en) * 2001-01-23 2001-03-07 Glaxo Group Ltd Novel protein
KR20040011480A (ko) * 2001-03-22 2004-02-05 덴드레온 샌 디에고 엘엘씨 세린 프로테아제 ｃｖｓｐ14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1539942A4 (en) * 2001-05-14 2005-10-19 Dendreon Corp A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF
WO2003012038A2 (en) 2001-07-27 2003-02-13 Wyeth Aggrecanase molecules
WO2003027282A1 (fr) * 2001-09-24 2003-04-03 Daiichi Fine Chemical Co., Ltd. Adamts-15, -16, -17, -18 et -19
WO2003042379A2 (en) * 2001-11-13 2003-05-22 Universite De Liege A new disintegrin and metalloproteinase with thrombospondin type i repeats polynucleotide and its encoded polypeptide
WO2003064651A2 (en) * 2002-01-28 2003-08-07 Bayer Healthcare Ag Regulation of human membrane-type serine protease
EP2341350B1 (en) * 2003-09-20 2017-11-08 Electrophoretics Limited Diagnostic method for brain damage-related disorders based on detection of dj-1
US20080248462A1 (en) * 2003-10-21 2008-10-09 Baayer Healhcare Ag Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase (Aminopeptidase B)-Like 1 (Rnpepl1)
WO2005106021A1 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 8 (dpp8)
WO2005118632A1 (en) * 2004-05-27 2005-12-15 Vib Vzw A NOVEL HUMAN CARD-ONLY PROTEIN THAT INHIBITS PRO-IL-1β MATURATION
EP2032701B1 (en) * 2006-06-23 2013-11-27 Alethia Biotherapeutics Inc. Polynucleotides and polypeptides involved in cancer
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008063382A2 (en) 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonists of pcsk9
CA2680832A1 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
CN103492418B (zh) 2011-03-31 2016-06-29 阿莱斯亚生物疗法股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
BR112014016723A2 (pt) 2012-01-09 2018-07-24 Alethia Biotherapeutics Inc. método para o tratamento de câncer de mama
CA2875096A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20180237787A1 (en) 2016-12-23 2018-08-23 President And Fellows Of Harvard College Gene editing of pcsk9

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932422A (en) * 1997-11-14 1999-08-03 Millennium Pharmaceuticals, Inc. Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
EP1165123A4 (en) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 48 HUMAN SECRETED PROTEINS
WO2002000860A2 (en) * 2000-06-26 2002-01-03 Sugen, Inc. Novel proteases

Also Published As

Publication number Publication date
AU2001269836A1 (en) 2002-01-02
WO2001098468A3 (en) 2003-01-03
EP1292684A2 (en) 2003-03-19
WO2001098468A2 (en) 2001-12-27
JP2004515217A (ja) 2004-05-27

Similar Documents

Publication Publication Date Title
CA2411971A1 (en) Proteases
US20050101529A1 (en) Protein modification and maintenance molecules
US20040023243A1 (en) Proteases
US20050142600A1 (en) Protein modification and maintenance molecules
CA2416691A1 (en) Proteases
WO2003000844A2 (en) Protein modification and maintenance molecules
CA2425829A1 (en) Proteases
CA2412872A1 (en) Protein modification and maintenance molecules
CA2402763A1 (en) Proteases
CA2434953A1 (en) Protein modification and maintenance molecules
CA2409315A1 (en) Protein phosphatases
US20050227280A1 (en) Proteases
WO2004053068A2 (en) Protein modification and maintenance molecules
WO2002020736A2 (en) Proteases
CA2394789A1 (en) Proteases
EP1434785A2 (en) Protein modification and maintenance molecules
US20050019763A1 (en) Protein modification and maintenance molecules
US20040081961A1 (en) Proteases
US20030124706A1 (en) Proteases
US20040029249A1 (en) Proteases
US20040091962A1 (en) Proteases

Legal Events

Date Code Title Description
FZDE Dead